フルテキストURL fulltext.pdf
著者 Ichihara, Eiki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
キーワード lung cancer interstitial pneumonia
発行日 2020-01-15
出版物タイトル Internal Medicine
59巻
2号
出版者 日本内科学会
開始ページ 163
終了ページ 167
ISSN 0918-2918
NCID AA10827774
資料タイプ 学術雑誌論文
言語 English
著作権者 © 2020 by The Japanese Society of Internal Medicine
論文のバージョン publisher
PubMed ID 31534086
NAID 130007785095
DOI 10.2169/internalmedicine.3481-19
Web of Science KeyUT 000507577600002
関連URL isVersionOf https://doi.org/10.2169/internalmedicine.3481-19
JaLCDOI 10.18926/AMO/60802
フルテキストURL 74_5_423.pdf
著者 Hirabae, Atsuko| Ichihara, Eiki| Sunami, Ryota| Ota, Moeko| Iwamoto, Yoshitaka| Maeda, Yoshinobu| Kiura, Katsuyuki|
抄録 We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
キーワード lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression
Amo Type Case Report
発行日 2020-10
出版物タイトル Acta Medica Okayama
74巻
5号
出版者 Okayama University Medical School
開始ページ 423
終了ページ 425
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 33106698
フルテキストURL fulltext.pdf
著者 Kano, Hirohisa| Ichihara, Eiki| Harada, Daijiro| Inoue, Koji| Kayatani, Hiroe| Hosokawa, Shinobu| Kishino, Daizo| Watanabe, Kazuhiko| Ochi, Nobuaki| Oda, Naohiro| Hara, Naofumi| Ninomiya, Kiichiro| Hotta, Katsuyuki| Maeda, Yoshinobu| Kiura, Katsuyuki|
キーワード immune checkpoint inhibitor non-small cell-lung cancer PD-L1 pembrolizumab poor performance status
発行日 2020-07-29
出版物タイトル Cancer Science
111巻
10号
出版者 Wiley
開始ページ 3739
終了ページ 3746
ISSN 1347-9032
NCID AA11808050
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © 2020 The Authors.
論文のバージョン publisher
PubMed ID 32726470
DOI 10.1111/cas.14590
Web of Science KeyUT 000562490200001
関連URL isVersionOf https://doi.org/10.1111/cas.14590
フルテキストURL fulltext.pdf
著者 Matsuoka, Natsumi| Tsuji, Kenji| Ichihara, Eiki| Hara, Takayuki| Fukushima, Kazuhiko| Toma, Kishio| Kitamura, Shinji| Inagaki, Kenichi| Sugiyama, Hitoshi| Wada, Jun|
キーワード Pembrolizumab Hypothyroidism Creatinine Cystatin C
発行日 2020-03-31
出版物タイトル BMC Nephrology
21巻
出版者 BMC
開始ページ 113
ISSN 1471-2369
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © The Author(s). 2020
論文のバージョン publisher
PubMed ID 32234009
DOI 10.1186/s12882-020-01775-z
Web of Science KeyUT 000522961400004
関連URL isVersionOf https://doi.org/10.1186/s12882-020-01775-z
JaLCDOI 10.18926/AMO/58271
フルテキストURL 74_2_129.pdf
著者 Fukuma, Shogo| Shinya, Takayoshi| Soh, Junichi| Fukuhara, Ryuichiro| Ogawa, Nanako| Higaki, Fumiyo| Tanaka, Takehiro| Ichihara, Eiki| Hiraki, Takao| Toyooka, Shinichi| Kanazawa, Susumu|
抄録 The aim of this study was to explore enhancement patterns of different types of primary lung cancers on 2-phase dynamic computed tomography (CT). This study included 217 primary lung cancer patients (141 adenocarcinomas [ADs], 48 squamous cell carcinomas [SCCs], 20 small cell lung carcinomas [SCLCs], and 8 others) who were examined using a 2-phase dynamic scan. Regions of interest were identified and mean enhancement values were calculated. After excluding the 20 SCLCs because these lesions had different clinical stages from the other cancer types, the mean attenuation values and subtractions between phases were compared between types of non-small cell lung carcinomas (NSCLCs) using the Kruskal–Wallis test. Late phase attenuation and attenuation of the late minus unenhanced phase (LMU) of SCCs were significantly higher than those of ADs (p<0.05). To differentiate SCC and AD in the late phase, a threshold of 80.21 Hounsfield units (HU) gave 52.9% accuracy. In LMU, a threshold of 52.16 HU gave 59.3% accuracy. Dynamic lung CT has the potential to aid in differentiating among NSCLC types.
キーワード differentiation dynamic computed tomography primary lung cancer enhancement pattern
Amo Type Original Article
発行日 2020-04
出版物タイトル Acta Medica Okayama
74巻
2号
出版者 Okayama University Medical School
開始ページ 129
終了ページ 135
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 32341587
Web of Science KeyUT 000528278500006
NAID 120006839450
フルテキストURL J_Thorac_Oncol_201907017.pdf
著者 Makimoto, Go| Ohashi, Kadoaki| Tomida, Shuta| Nishii, Kazuya| Matsubara, Takehiro| Kayatani, Hiroe| Higo, Hisao| Ninomiya, Kiichiro| Sato, Akiko| Watanabe, Hiromi| Kano, Hirohisa| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Takata, Minoru| Maeda, Yoshinobu| Kiura, Katsuyuki|
キーワード ALK G1202R Alectinib Amphiregulin MET NSCLC
発行日 2019-07-30
出版物タイトル Journal of Thoracic Oncology
14巻
11号
出版者 Elsevier
開始ページ 2009
終了ページ 2018
ISSN 15560864
NCID AA12058455
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
論文のバージョン author
PubMed ID 31374369
DOI 10.1016/j.jtho.2019.07.017
Web of Science KeyUT 000492678300025
関連URL isVersionOf https://doi.org/10.1016/j.jtho.2019.07.017
JaLCDOI 10.18926/AMO/55446
フルテキストURL 71_5_453.pdf
著者 Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki|
抄録 Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.
キーワード chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure
Amo Type Clinical Study Protocol
発行日 2017-10
出版物タイトル Acta Medica Okayama
71巻
5号
出版者 Okayama University Medical School
開始ページ 453
終了ページ 457
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2017 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29042706
JaLCDOI 10.18926/AMO/54499
フルテキストURL 70_4_243.pdf
著者 Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki|
抄録 Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p<0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.
キーワード vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse
Amo Type Original Article
発行日 2016-08
出版物タイトル Acta Medica Okayama
70巻
4号
出版者 Okayama University Medical School
開始ページ 243
終了ページ 253
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27549668
Web of Science KeyUT 000384748600003
著者 Harada, Daijiro| Takigawa, Nagio| Ochi, Nobuaki| Ninomiya, Takashi| Yasugi, Masayuki| Kubo, Toshio| Takeda, Hiromasa| Ichihara, Eiki| Ohashi, Kadoaki| Takata, Saburo| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2012-10
出版物タイトル Cancer Science
103巻
10号
資料タイプ 学術雑誌論文
著者 Kubo, Toshio| Takigawa, Nagio| Osawa, Masahiro| Harada, Daijiro| Ninomiya, Takashi| Ochi, Nobuaki| Ichihara, Eiki| Yamane, Hiromichi| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2013-01
出版物タイトル Cancer Science
104巻
1号
資料タイプ 学術雑誌論文
著者 Rai, Kammei| Takigawa, Nagio| Ito, Sachio| Kashihara, Hiromi| Ichihara, Eiki| Yasuda, Tatsuji| Shimizu, Kenji| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2011-09
出版物タイトル Molecular Cancer Therapeutics
10巻
9号
資料タイプ 学術雑誌論文
著者 頼 冠名| 瀧川 奈義夫| 伊藤 佐智夫| 柏原 宏美| 市原 英基| 保田 立二| 清水 憲二| 谷本 光音| 木浦 勝行|
発行日 2012-12-03
出版物タイトル 岡山医学会雑誌
124巻
3号
資料タイプ 学術雑誌論文